A modeling study comparing the cost-effectiveness of gene therapy versus common care for patients with sickle cell disease found that gene therapy is beneficial in this patient population and likely cost-effective if the price stays below $2 million per person. The findings are published in Annals of Internal Medicine.
from Medical Xpress - latest medical and health news stories https://ift.tt/Yju3Ivq
